NASDAQ$SANA
Sana Biotechnology Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Sana reported financial results and business highlights.
Sana Biotechnology reported a net income of $1.0 million for Q3 2023, with a cash position of $268.6 million expected to last into 2025. The company is focused on developing its hypoimmune technology and anticipates data from multiple clinical settings in 2023 and 2024.
- Enrollment continues in the ARDENT Phase 1 study, with initial clinical data expected in 2023 and more robust data in 2024.
- A CTA was submitted for an investigator-sponsored trial evaluating HIP-modified primary islet cells in patients with type 1 diabetes, with initial proof of concept data expected in 2023 and 2024.
- An IND was submitted for SC291 for the treatment of multiple B-cell-mediated autoimmune diseases, with preliminary clinical data expected in 2024.
- The IND is on track for submission in 4Q 2023 for SC262 for the treatment of B-cell lymphomas and leukemias in patients who have failed CD19-directed CAR T therapies, with preliminary clinical data expected in 2024.
Headline financials
Revenue & EPS history
Sana · Revenue · Quarterly
$0
Forward guidance
Sana Biotechnology expects 2024 operating cash burn to be below $200 million, enabling multiple clinical data readouts with its current balance sheet and a cash runway into 2025.
Tailwinds
- Initial clinical data from the ARDENT Phase 1 study expected in 2023, with more robust data expected in 2024.
- Initial HIP proof of concept data from the IST evaluating HIP-modified primary islet cells in patients with type 1 diabetes expected in 2023 and 2024.
- Preliminary clinical data from SC291 for the treatment of multiple B-cell-mediated autoimmune diseases expected in 2024.
- Preliminary clinical data from SC262 for the treatment of B-cell lymphomas and leukemias expected in 2024.
- Cash position of $268.6 million expected to last into 2025, supporting activities through multiple data readouts.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
-1.2%
Avg return
Earnings day
-2.0%
Avg return
5 days after
+4.1%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+22.3%
Q2 2022
Best reaction
-25.3%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.5% | -15.3% | -18.6% | |
| Q3 2025 | -0.2% | +3.9% | +25.7% | |
| Q2 2025 | +7.3% | +14.0% | +16.4% | |
| Q1 2025 | +0.6% | -1.7% | +56.9% | |
| Q4 2024 | -17.7% | -16.6% | -40.4% | |
| Q3 2024 | -6.8% | -14.2% | -25.8% | |
| Q1 2024 | -25.3% | -21.2% | -30.5% | |
| Q4 2023 | +5.6% | -8.1% | -6.3% | |
| Q3 2023 | -14.8% | -10.3% | -4.1% | |
| Q2 2023 | -3.8% | -1.3% | -4.5% | |
| Q1 2023 | +7.2% | +11.8% | +8.9% | |
| Q4 2022 | +2.3% | +2.3% | +51.8% | |
| Q3 2022 | -14.1% | -21.6% | -22.2% | |
| Q2 2022 | +22.3% | +18.3% | -3.0% | |
| Q1 2022 | -5.6% | -11.9% | -11.4% | |
| Q4 2021 | +21.1% | +19.5% | +45.6% | |
| Q3 2021 | -5.7% | -3.3% | -19.2% | |
| Q2 2020 | +10.2% | +9.5% | +40.5% | |
| Q2 2021 | +10.2% | +9.5% | +40.5% | |
| Q1 2021 | -13.1% | -1.9% | +9.9% | |
| Q4 2020 | -5.7% | -4.1% | -23.7% | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro